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Abstract 
Seborrheic keratoses (SK) are the most common skin tumour of humanity. The incidence of this purely benign 
epithelial proliferation is increasing with age and exposure to ultraviolet light. It has a remarkable variability in its 
clinical presentation raising some differential diagnoses. Recently, oncogenic mutations have been detected 
involved in the development of SK, which, however, do not bear the risk of malignant transformation. SK may also 
develop with the use of modern targeted drugs for the treatment of malignancies. The classical treatment options 
for SK are cryotherapy and curettage. Recently, topical treatment with 40% hydrogen peroxide and the nitric-zinc 
complex has been investigated. Ablative laser therapy is an effective treatment as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Seborrheic keratoses (SKs) are the most 
common benign epithelial tumours of humanity with 
an increasing incidence with age. The predilection 
zones of SKs are trunk and forehead. An important 
clinical sign is the formation of multiple horn pearls [1]. 
In dermoscopy, comedo-like openings, milia-like 
cysts, and fissures and ridges are characteristic [2]. 
Although most SKs have a maximum diameter of less 
than 4 cm, sometimes giant lesions develop that 
raises some possible differential diagnoses including 
Buschke-Löwenstein tumours [3]. 
On the histologic level six subtypes can be 
differentiated: - hyperkeratotic type; - acanthotic type; 
- reticular/adenoid type; - clonal type; - irritated type;   
- melanoakanthoma [1]. 
Multiple eruptive SKs was known as Leser-
Trélat-syndrome gain importance as a paraneoplasia 
[4]. 
 
 
Pathogenesis 
 
The etiopathology of SKs is not completely 
understood. They are considered a sign of ageing skin 
and UV-exposure may be associated with. The viral 
hypothesis is suggesting the involvement of human 
papillomavirus has not been substantiated by recent 
studies [5], [6]. 
Expression of the amyloid precursor protein 
(APP) has been evaluated in SKs versus normal skin 
by immunohistochemistry, Western blotting and 
quantitative real-time polymerase chain reaction 
(PCR). APP and its downstream products (i.e. 
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amyloid-β42) were stronger expressed in SK than in 
paired adjacent normal skin tissues. In contrast, the 
expression of its key secretase (i.e. β-secretase1) was 
low. Furthermore, APP expression was higher in UV-
exposed than non-exposed skin sites and the older 
age group. APP expression correlated positively with 
age in the epidermis (p < 0.05), but not in the dermis. 
These findings suggest that overexpression of APP 
may promote the onset of SK and is a marker of skin 
ageing and UV damage [7].  
Exome sequencing of SKs indicated three 
mutations per megabase pairs of the targeted 
sequence. The mutational pattern depicted typical UV 
signature with the majority of alterations being C > T 
and CC > TT base changes at dipyrimidinic sites. The 
FGFR3 mutations were the most frequent, detected in 
48% of lesions, followed by the PIK3CA (32%), TERT 
promoter (24%) and DPH3 promoter mutations (24%) 
[8]. 
Neel et al., (2016) investigated SKs, which 
frequently have acquired oncogenic mutations in the 
receptor tyrosine kinase/phosphatidylinositol 3-
kinase/Akt signalling cascade. They demonstrated 
that SKs have a hypersensitivity to Akt inhibition. 
FoxN1 is a novel biomarker of the oncogenically 
activated but benign phenotype in SKs. They also 
established that Akt inhibition caused an increase in 
p53 protein expression, but not RNA expression and 
that Akt-mediated apoptosis was dependent on p53 
and FoxO3, a target of Akt [9]. 
 
 
Hyperkeratotic type 
 
The histologic feature of this common subtype 
is orthohyperkeratosis with papillomatosis. Acanthosis 
is mild or absent. Horn pearls are missing (Figure 1) 
[1]. 
 
Figure 1: Hyperkeratotic seborrheic keratosis 
This is the most common subtype (Figure 2). 
The tumours are characterised by huge acanthosis 
but mild or missing hyperkeratosis and papillomatosis. 
Horny invaginations that on cross-sections appear as 
“pseudo-horn cysts” are numerous. True horn cysts 
are also seen, which show sudden and complete 
keratinisation with a very thin granular layer 
surrounding it [1].  
 
Figure 2: Dermoscopic presentation of acanthotic seborrheic 
keratosis with multiple pseudo-horn cysts 
 
 
Reticular or adenoid type 
 
The SKs of this subtype is characterised by 
reticular acanthosis of thin, double row with mild to 
moderate hyperkeratosis and papillomatosis. These 
SKs are often hyperpigmented. Horn pearls are 
uncommon. This subtype is more common in sun-
exposed areas (Figures 3 and 4) [10]. 
 
Figure 3: Hyperpigmented adenoid seborrheic keratosis of the vulva 
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Figure 4: Reticular seborrheic keratosis with an oak-leave 
appearance 
 
 
Clonal type 
 
In this type marked acanthosis and 
papillomatosis are associated with 
orthohyperkeratosis. Tumour cells are spindle-
shaped. With a tumour demarcated tumour, islands of 
basaloid cell nests are found. Major differential 
diagnosis to clinal SK is pagetoid Bowen’s disease 
(Figure 5). Immunohistochemistry may be helpful in 
selected cases to distinguish both entities. 
Cytokeratin-10 is more expressed in clonal SK, while 
increased Ki-67-positive cells and the presence of > 
75% positive p16 cells is in favour of pagetoid 
Bowen’s disease [11]. 
 
Figure 5: Giant hyperpigmented clonal seborrheic keratosis 
resembling Buschke-Löwenstein a tumour 
 
 
Irritated type 
 
Here, a proliferation of spindle-shaped 
eosinophilic tumours cells is found, sometimes in 
whorl-like formations. Dyskeratotic cells may be 
present. In clinical practice, it is important to separate 
irritated SK from cutaneous squamous cell carcinoma 
(SCC) (Figure 6). Immunohistochemistry may be 
helpful to distinguish both entities. In a recent study, 
the combination of U3 small nucleolar 
ribonucleoprotein protein IMP3 and B-cell lymphoma 2 
regulatory protein (BCL-2) may has been shown 
diagnostic utility in distinguishing between irritated SK 
and SCC in daily clinical practice while epidermal 
growth factor receptor (EGFR) immunohistochemistry 
did not appear to be useful in this setting [12]. 
 
Figure 6: Irritated seborrheic keratosis resembling cutaneous 
squamous cell carcinoma 
 
In the illustrated case of an SK prepatellar, 
koilocytes were present as a histological sign of a 
secondary viral infection. A higher prevalence of 
human papillomavirus p16 expression has been found 
preferably in genital SKs with 65% to 69.6% [13], [14]. 
The prevalence is lower in vulvar SKs in women older 
than 50 years with 14.3% [15]. Herpes virus 6A is 
another virus that can be detected in SKs [16]. In a 
recent study, Merkel cell polyomavirus could be 
detected in 6 of 23 SKs by polymerase chain reaction 
(PCR) and fluorescence in situ hybridisation (FISH) 
[14]. Expression of p16 and p21 had been detected in 
SKs with Bowenoid transformation [17].  
With the development of checkpoint inhibitors, 
new adverse events have been seen in treated 
patients. Rhambia et al., (2018) reported on 
inflammatory reactions in SKs induced by 
programmed cell death-1 (PD1) inhibitor nivolumab. 
Chronic viral infections are known to result in T-cell 
tolerance because of persistent antigen stimulation. A 
viral infection is a secondary event in SKs. PD-1 
inhibition can reinvigorate exhausted T cells, which 
are accordingly able to decrease viral load. Thus, the 
inflammatory reaction of SKs may be the result of PD-
1 inhibition reactivating virally driven T lymphocytes 
[18]. 
LL-37 is a naturally occurring 37-amino-acid 
peptide that is part of the innate immune system in 
human skin. Studies have shown that intra-tumoral 
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injections of LL-37 stimulate the innate immune 
system by activation of plasmacytoid dendritic cells, 
which mediate tumour destruction. It has been 
reported that LL-37 induces an inflammatory response 
to SKs characterised by a lichenoid cellular infiltrate 
[19]. 
 
 
Melanoakanthoma 
 
This is the hyperpigmented acanthotic type 
with a proliferation of basaloid cells with mild or even 
absent hyperkeratosis. Numerous melanocytes are 
intermingled. Melanophages are located within the 
dermis underneath a tumour (Fig. 7) [1]. 
 
Figure 7: Melanoacanthoma with prominent horn cysts 
 
 
Treatment 
 
Patients have wide ranges of motivations for 
treating or removing SKs, including embarrassment 
from the stigmatising appearance of the lesion, 
physical irritation or pruritus, and a desire to look 
younger [20].  
Lesions that are inflamed, bleeding, ulcerated, 
or sufficiently irritated should be further characterised 
by a biopsy or excision to rule out malignancies [21]. 
Two recent randomised trials 
(ClinicalTrials.gov identifiers: NCT02667236 and 
NCT02667275) compared the safety and efficacy of 
40% hydrogen peroxide topical solution (HP40; 
ESKATA
TM
, Aclaris Therapeutics, Inc., Wayne, PA) 
versus vehicle (VEH) for the treatment of SKs. This 
trial included 937 patients with 4 SKs who were 
randomised 1:1 to HP40 or VEH.  
The clinical response was graded using the 
Physician's Lesion Assessment (PLA) scale (0: Clear; 
1: Near-Clear; 2: ≤ 1 mm thick, and 3: > 1 mm thick). 
After one treatment, SKs with PLA > 0 were re-treated 
3 weeks later. At day 106, significantly more HP40 
patients versus VEH achieved PLA = 0 on all 4 SKs 
(4% or 8% vs 0%) and 3 of 4 SKs (13% or 23 % vs 
0%). A higher mean per-patient percentage of SKs 
were Clear (25% vs 2 % or 34% vs 1%) and 
Clear/Near-Clear (47% vs 10% or 54% vs 5%) with 
HP40 versus VEH. Most local skin reactions were mild 
and resolved by day 106 [22]. HP40 may act not only 
through its direct oxidation of organic tissues, 
generation of reactive oxygen species, and local lipid 
peroxidation but also by the generation of local 
concentrations of oxygen that are toxic to SK cells [23] 
[24]. 
A nitric-zinc complex has been used to treat 
50 SK lesions. The topical formulation is an aqueous 
solution containing nitric acid, zinc and copper salts, 
and organic acids (acetic, lactic, and oxalic acid). 
Treatment consisted of the topical application to 
obtain a whitening or yellowish reaction on top of SKs. 
Application of the nitric-zinc solution was performed 
every other week until clinical and dermoscopic 
clearance or crust formation, for a maximum of 4 
applications. All subjects, who reported no or minimal 
discomfort during and after the application of the 
solution, completed the study. After eight weeks, 
complete clearance was observed in 37 lesions after 
an average of 3 applications/lesion. A partial 
response, with minimal persistent residual spots, was 
detected in the remaining 13 lesions. All patients with 
complete clearance showed no relapses at a 6-month 
follow-up [25].  
Case reports have been published with the 
successful use of either diclofenac gel, imiquimod, 
dobesilate or calcitriol [26], [27], [28], [29]. 
Patients preferred cryotherapy over curettage 
in a small trial (n = 25). But physicians rating observed 
more redness at 6 weeks and the tendency for 
hypopigmented scar formation at greater than 12 
months with curettage. Leftover SK lesion occurred 
more frequently with cryotherapy in the short and long 
term [30]. 
The use of ablative lasers and cryotherapy for 
SKs has a long tradition. But which method is better? 
A comparative trial was carried out on 42 patients with 
SK of 0.5-3 cm, located on the back, chest, face and 
neck. Lesions with a similar size and location on the 
same patient were matched. In the same session, half 
of the lesions were treated with cryotherapy, while the 
other half were treated with Er: YAG laser [31].  
Following the first treatment, complete healing 
was detected in all of the lesions (100%) treated with 
Er: YAG lasers, while the healing rate was 68% in the 
cryotherapy group (p < 0.01). In the Er: YAG laser-
treated group, hyperpigmentation was significantly 
lower and more erythema developed than in the 
cryotherapy group [31]. The results are in one line 
with our own experiences with Er: YAG laser [32].  
The CO2 laser is another opportunity but with 
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a higher risk of scarring and pigmentary changes [33]. 
Small case series have used intense pulsed light [34]. 
In conclusion, SKs are very common. Their 
clinical variability can confuse with other potentially 
malignant skin diseases. Treatment options include 
topical and surgical options. 
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